Nasdaq4d
Milestone Pharmaceuticals Inc. Announces Investor Event for Commercial Launch Plan of Etripamil Nasal Spray CARDAMYST™
Milestone Pharmaceuticals Inc. announced an investor event on February 25, 2025, in New York to discuss its commercial launch plan for etripamil nasal spray, also known as CARDAMYST™, which is ...
Milestone Pharmaceuticals to host Commercial Launch Plan investor event
Milestone announced further details on its in-person and virtual Commercial Launch Plan investor event to take place in New York on Tuesday, ...
Yahoo Finance3d
Milestone Pharmaceuticals Inc. (MIST)
PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in ...
rheumatologyadvisor2d
FDA Drug Approval Decisions Expected in March 2025
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...
pulmonologyadvisor4d
Nasal Spray Formulation of Bumetanide Under FDA Review
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
Quincy man becomes first Alzheimer’s patient to try nasal spray drug: ‘I’m hoping like heck’
Retired electrician Joe Walsh in December became the first Alzheimer’s patient to try a nasal spray used to treat other ...
Don’t use this nasal spray: FDA says it may cause ‘adverse’ effects
STATEN ISLAND, N.Y. — The U.S. Food and Drug Administration (FDA) has announced a recall of 89,312 bottles of a popular nasal ...
Over 89,000 Bottles of Nasal Spray Recalled By FDA—What to Know
There’s another recall to be aware of right now, and it involves nose spray. NeilMed Pharmaceuticals Inc., the manufacturer of NasoGel Spray, has issued an international recall of 89,312 of its sprays ...